Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06428669 · ClinicalTrials.gov registry record · Phase 4
Effect of Nitropaste in Chest Masculinizing Surgery
A Phase 4 study of Gender Dysphoria, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 256
- Enrollment target
- 1
- Study location
NCT06428669: Recruiting Phase 4 study of Gender Dysphoria, sponsored by University of Virginia.
NCT06428669 is a Phase 4 study of Gender Dysphoria that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 256 participants, above the 147-participant average among 8 other Gender Dysphoria trials with a reported enrollment target (74% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06428669, a Phase 4 study of Gender Dysphoria, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 256 participants
- Enrollment target
- 1
- Study location
Study Summary
Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and random pattern flaps. Furthermore, recent clinical studies highlight significantly decreased mastectomy flap wound complication and need for sharp debridement. Nitropaste has low rates of side effects and is very well tolerated in general. To this date, there's no study that investigates its utility on patients who are undergoing chest masculinizing surgery. The purpose of this study is to investigate the potential utility of nitropaste in reducing rates of wound complications in patients undergoing chest masculinizing surgery.
Conditions Studied
Interventions
- DRUG Nitro-Bid 2 % Topical Ointment
Study Locations (1)
Virginia
- University of Virginia Medical Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2025-11 |
| Phase | Phase 4 |
What NCT06428669 shows while recruiting
NCT06428669 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, above the 147-participant average among 8 other Gender Dysphoria trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Gender Dysphoria appearing as the primary indexed condition, and to 1 intervention - of which Nitro-Bid 2 % Topical Ointment is the first listed.
NCT06428669 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06428669 about?
NCT06428669 is a clinical study titled "Effect of Nitropaste in Chest Masculinizing Surgery". Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and r...
What is the current status of trial NCT06428669?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 256 participants. The study started on 2022-08-15. Estimated completion is 2025-11.
What conditions does trial NCT06428669 study?
This clinical trial studies the following conditions: Gender Dysphoria.
What interventions are being tested in trial NCT06428669?
The interventions under investigation include: Nitro-Bid 2 % Topical Ointment (DRUG).
Who is sponsoring clinical trial NCT06428669?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06428669 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gender Dysphoria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06428669's enrollment target sits among peer trials
256 2nd of 8 the highest of 8 other Gender Dysphoria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gender Dysphoria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RECRUITING
-
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy
RECRUITING · NA
-
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
RECRUITING · Phase 3
-
Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy
RECRUITING · Phase 3
-
Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy
ACTIVE NOT RECRUITING
-
Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI